8-K: HCA Healthcare Announces Q4 2023 Results, 2024 Guidance, CFO Retirement and New Share Repurchase Program

HCA Healthcare reported strong fourth-quarter results with increased revenues and adjusted EBITDA, announced the retirement of its CFO, and authorized a new $6 billion share repurchase program.

Summary

• HCA Healthcare reported its financial and operating results for the fourth quarter and year ended December 31, 2023.
• Fourth-quarter revenues reached $17.303 billion, up from $15.497 billion in the same period of 2022.
• Net income attributable to HCA Healthcare for the fourth quarter was $1.607 billion, or $5.93 per diluted share, compared to $2.081 billion, or $7.28 per diluted share, in the fourth quarter of 2022.
• Adjusted EBITDA for the fourth quarter totaled $3.618 billion, compared to $3.179 billion in the fourth quarter of 2022.
• For the full year 2023, revenues were $64.968 billion, compared to $60.233 billion in 2022.
• Full-year net income attributable to HCA Healthcare was $5.242 billion, or $18.97 per diluted share, compared to $5.643 billion, or $19.15 per diluted share, in 2022.
• Adjusted EBITDA for the full year 2023 was $12.726 billion, compared to $12.067 billion in 2022.
• The company's board authorized a new share repurchase program of up to $6 billion.
• A quarterly cash dividend of $0.66 per share was declared, payable on March 29, 2024.
• The company provided 2024 guidance, projecting revenues between $67.75 and $70.25 billion, net income between $5.20 and $5.60 billion, and adjusted EBITDA between $12.85 and $13.55 billion.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong revenue and EBITDA growth, a new share repurchase program, and a dividend announcement. However, the decrease in net income and the retirement of the CFO introduce some uncertainty.

Positives

• HCA Healthcare experienced strong demand for services across its diversified portfolio.
• The company saw improved cost trends in the fourth quarter.
• Same facility revenue per equivalent admission increased by 6.9 percent in the fourth quarter.
• Cash flows from operating activities in the fourth quarter of 2023 totaled $2.674 billion.
• The company repurchased 3.647 million shares of its common stock at a cost of $910 million during the fourth quarter.
• The company has $6.107 billion of availability under its credit facilities as of December 31, 2023.

Negatives

• Net income attributable to HCA Healthcare, Inc. decreased in the fourth quarter of 2023 compared to the same period in 2022, from $2.081 billion to $1.607 billion.
• Net income attributable to HCA Healthcare, Inc. decreased for the full year 2023 compared to 2022, from $5.643 billion to $5.242 billion.
• The company experienced losses on sales of facilities of $5 million for the year ended December 31, 2023.

Risks

• The company's 2024 guidance is subject to various uncertainties and risks, including changes in economic conditions, patient volumes, and payer mix.
• The company faces risks related to potential federal government shutdowns, health reform initiatives, and changes in Medicare and Medicaid programs.
• There are risks associated with personnel-related capacity constraints, increases in wages, and the ability to attract and retain qualified staff.
• The company is exposed to risks related to cybersecurity incidents and data breaches.
• The company faces risks related to natural disasters and climate change.
• The company is subject to various legal and regulatory risks.

Future Outlook

HCA Healthcare provided 2024 guidance, projecting revenues between $67.75 and $70.25 billion, net income between $5.20 and $5.60 billion, and adjusted EBITDA between $12.85 and $13.55 billion. Capital expenditures for 2024 are estimated to be in the range of $5.1 to $5.3 billion.

Management Comments

• Sam Hazen, Chief Executive Officer of HCA Healthcare, stated that the company experienced strong demand for services and improved cost trends in the fourth quarter.
• Sam Hazen thanked the company's people for their hard work and contributions.
• Sam Hazen acknowledged Bill Rutherford's contributions and legacy as CFO.
• Sam Hazen expressed confidence in Mike Marks' ability to continue to advance the company's success as the new CFO.

Industry Context

This announcement reflects the ongoing trends in the healthcare industry, including the demand for services, cost management pressures, and the importance of financial performance. The leadership transition is a common occurrence in large corporations, and the share repurchase program indicates a focus on shareholder value.

Comparison to Industry Standards

• HCA's revenue growth of 11.6% in Q4 2023 compared to Q4 2022 is strong, outpacing some competitors like Tenet Healthcare which reported a 7.5% increase in net operating revenues for the same period.
• HCA's adjusted EBITDA margin of 20.9% in Q4 2023 is competitive with other large hospital operators, although some specialized healthcare providers may have higher margins.
• The $6 billion share repurchase program is a significant move, indicating confidence in future cash flows and a commitment to returning value to shareholders, similar to actions taken by other large healthcare companies like UnitedHealth Group.
• HCA's same-facility admission growth of 3.1% is a positive sign, indicating organic growth in patient volumes, which is a key metric for hospital operators.
• The company's 2024 guidance for revenue and EBITDA is in line with analyst expectations for the sector, suggesting a stable outlook for the coming year.

Management Changes

Stakeholder Impact

• Shareholders will benefit from the share repurchase program and the dividend payment.
• Employees will experience a change in leadership with the retirement of the CFO.
• Customers will continue to receive healthcare services from HCA facilities.
• Creditors will be impacted by the company's financial performance and debt management.

Next Steps

• The company will execute the $6 billion share repurchase program.
• The company will pay a quarterly cash dividend of $0.66 per share on March 29, 2024.
• Michael A. Marks will assume the role of Executive Vice President and Chief Financial Officer on May 1, 2024.
• The company will hold its annual stockholders meeting virtually on April 25, 2024.
• The company will continue to monitor and manage the risks and uncertainties outlined in the forward-looking statements.

Key Dates

Keywords

HCA Healthcare, Financial Results, Share Repurchase, Dividend, CFO Retirement, Executive Appointment, Healthcare, Hospital, EBITDA, Revenue, Net Income